Earle A. Chiles Research Institute

  • Clinical trials: Leading breakthroughs in cancer research

    Clinical trials: Leading breakthroughs in cancer research

    May 20 is International Clinical Trials Day. Clinical trials are evidence-based studies in people that result in the biggest breakthroughs in cancer research.

    Read Article
  • Woman with pancreatic cancer grateful for personalized immunotherapy

    Woman with pancreatic cancer grateful for personalized immunotherapy

    Florida woman with metastatic pancreatic cancer participates in groundbreaking clinical trial of adoptive cellular therapy only available at Providence Cancer Institute.

    Read Article
  • Studies will evaluate combination therapies for two types of melanoma

    Studies will evaluate combination therapies for two types of melanoma

    Two new clinical trials available at Providence will evaluate whether a combination of medications are effective and safe therapies for people with metastatic melanoma and metastatic uveal melanoma.

    Read Article
  • Oregon hosts global immunology conference featuring Providence immuno-oncology research

    Oregon hosts global immunology conference featuring Providence immuno-oncology research

    Researchers of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, will present their latest cancer immunotherapy data at Immunology2022 in May.

    Read Article
  • New study evaluates immunoradiotherapy treatment for head and neck cancer patients

    New study evaluates immunoradiotherapy treatment for head and neck cancer patients

    Investigator-initiated clinical trial at Providence Cancer Institute to evaluate the safety and efficacy of using a combination of immunotherapy and radiation therapy on tumors.

    Read Article
  • Study to evaluate effect of immunotherapy in blood cancer

    Study to evaluate effect of immunotherapy in blood cancer

    A new phase I clinical trial available at Providence Cancer Institute of Oregon will evaluate the efficacy of new immunotherapy designed to modulate the immune system in blood cancer patients.

    Read Article
  • Three studies concentrate on personalized treatment for colon cancer

    Three studies concentrate on personalized treatment for colon cancer

    Clinical studies focus on finding new ways to treat colorectal cancer, prevent recurrence and improve survival outcomes.

    Read Article
  • Three studies focus on improving treatments for gastrointestinal cancers

    Three studies focus on improving treatments for gastrointestinal cancers

    People with gallbladder cancer, bile duct cancer or pancreatic cancer may be eligible to participate in new clinical trials available at Providence Cancer Institute of Oregon.

    Read Article
  • Cancer Moonshot relaunch aligns with Providence initiatives to reduce cancer burden and improve health equity

    Cancer Moonshot relaunch aligns with Providence initiatives to reduce cancer burden and improve health equity

    Providence initiatives in genomic medicine, immunotherapy research and cancer screening support Cancer Moonshot's goal to decrease the death rate from cancer by 50 percent in 25 years.

    Read Article
  • Clinical trial aims to help premenopausal women at risk for ovarian cancer

    Clinical trial aims to help premenopausal women at risk for ovarian cancer

    Researchers at Providence Cancer Institute are studying how well two surgical procedures work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

    Read Article
  • Jenny’s story: A young mother’s journey through cancer and COVID-19

    Jenny’s story: A young mother’s journey through cancer and COVID-19

    How Providence caregivers helped a young mother of four navigate COVID-19 and overcome a devastating cancer diagnosis.

    Read Article
  • New clinical study for people with advanced or metastatic lung cancer

    New clinical study for people with advanced or metastatic lung cancer

    A new study at Providence Cancer Institute tests the effectiveness of an experimental treatment and chemotherapy to inhibit tumor growth in people with lung cancer.

    Read Article
  • Ask an expert: Why do nonsmokers get lung cancer?

    Ask an expert: Why do nonsmokers get lung cancer?

    While tobacco is by far the leading cause of lung cancer, it's not the only contributor. Learn about other significant risk factors and what you can do to protect yourself and your loved ones.

    Read Article
  • Providence immunotherapy research presented at global conference

    Providence immunotherapy research presented at global conference

    Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, joined leading cancer immunotherapy professionals around the world for the largest

    Read Article
  • New clinical studies for invasive breast cancer

    New clinical studies for invasive breast cancer

    Providence Cancer Institute breast cancer experts are researching new treatments for women with triple-negative breast cancer and HER-2 positive breast cancer.

    Read Article
  • New research laboratory employs biomedical engineering for precision cancer surgery

    New research laboratory employs biomedical engineering for precision cancer surgery

    Experts in biomedical engineering, immunology and surgical oncology are working collaboratively to improve outcomes for people with head, neck and other cancers.

    Read Article
  • CAR T-cell therapy for advanced kidney cancer

    CAR T-cell therapy for advanced kidney cancer

    Providence Cancer Institute to open new clinical study of CAR T-cell therapy to people with clear cell renal cell carcinoma, the most common type of kidney cancer.

    Read Article
  • First-in-human immune therapy study for multiple myeloma

    First-in-human immune therapy study for multiple myeloma

    First-in-human immune therapy study at Providence Cancer Institute will assess the safety and effectiveness of talquetamab as a potential treatment for cancerous plasma cells known as multiple myeloma

    Read Article
  • Federal grant fuels research in harnessing micro-organisms for cancer immunotherapy

    Federal grant fuels research in harnessing micro-organisms for cancer immunotherapy

    Providence researchers awarded funding from National Cancer Institute to study “Bugs as Drugs.”

    Read Article
  • Providence first in Pacific NW to achieve national accreditation for Rectal Cancer Program

    Providence first in Pacific NW to achieve national accreditation for Rectal Cancer Program

    Providence Cancer Institute’s Rectal Cancer Program among the first 25 in the nation to earn accreditation from the National Accreditation Program for Rectal Cancer.

    Read Article
  • loading
    Loading More...